8Harvey, P. Cytochrome P450 enzymes: interpretation of their interactions with selective serotonin reuptake inhibitors. Part Ⅱ [J]. J Clin Psychopharmacol, 1996,16:345-355
9Carson SW. Pharmacokinetic and pharmacodynamic drug interactions with polypharmocotherapy of treatment-resistant affective and obsessivecompulsive disorders[J]. Psycopharmcol Bull, 1996,32: 555-568
10Shader RI, Von Moltke LL, Schmider J, et al. The clinician and drug interactions-an update[J] .J Clin Psychopharmacol, 1996,16:197-201
4McBane S, Trewet CB, Havican SN, et al. ACCP White Paper Te- nets for Developing Quality Measures for Ambulatory Clinical Pharmacy Services American College of Clinical Pharmacy[J]. Pharmacotherapy,2011,31 (7):723 -723.
5Oladapo AO, Barrier JC, Rascati KL. The need for more evi- dence-based studies to justify the economic value for the provi- sion of medication therapy management and other clinical phar- macy services[J]. Clin Ther,2012,34(11):2196-2199.
6Lee VW, Yi PT, Kong KW, et al. Impact of pharmacy outreach ser- vices on blood pressure management in the elderly community of Hong Kong[J]. Gerialr Gerontol Int,2013,13(1): 175-181.
